Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRK1 | P41145 | 10/20 | 1.00 |
| ▸ | OPRM1 | P35372 | 9/20 | 1.00 |
| ▸ | OPRD1 | P41143 | 9/20 | 1.00 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.68 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Etorphine SCHEMBL25681403 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL12125405 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL12230551 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL140251 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL19565627 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL19564457 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL10031275 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL14516216 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL29381660 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 | |
| Etorphine SCHEMBL20507 | 1.00 | OPRK1 (1.00) | OPRK1OPRM1OPRD1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2968129-A1 | ABUSE RESISTANT CAPSULE | R.P. Scherer Technologies, LLC (US) | 2016-01-20 | — | — | EP | claimed |
| WO-2014140231-A1 | ABUSE RESISTANT CAPSULE | WENGNER SIMONE (DE) | 2014-09-18 | — | — | WO | claimed |
| EP-1558257-B1 | DOSAGE FORM THAT IS SAFEGUARDED FROM ABUSE | GRUENENTHAL GMBH (DE) | 2013-12-25 | — | — | EP | claimed |
| WO-2023239688-A1 | METHODS AND DEVICES FOR GENERATING CORE-SHELL DROPLETS AND PARTICLES | THE TRUSTEES OF PRINCETON UNIVERSITY (US) | 2023-12-14 | — | — | WO | disclosed |
| US-20230330044-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS INC (US) | 2023-10-19 | — | — | US | disclosed |
| EP-4228608-A1 | CONTROLLED RELEASE FILL COMPOSITIONS AND CAPSULES CONTAINING SAME | R.P. Scherer Technologies, LLC (US) | 2023-08-23 | — | — | EP | disclosed |
| US-11723885-B2 | Methods and compositions for interfering with extraction or conversion of a drug susceptible to abuse | ACURA PHARMACEUTICALS, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| WO-2022081848-A1 | CONTROLLED RELEASE FILL COMPOSITIONS AND CAPSULES CONTAINING SAME | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2022-04-21 | — | — | WO | disclosed |
| US-11077196-B2 | Abuse-deterrent pharmaceutical composition | G.L. PHARMA GmbH (AT) | 2021-08-03 | — | — | US | disclosed |
| EP-3151819-B1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS INC (US) | 2020-08-05 | — | — | EP | disclosed |
| US-10653776-B2 | Compositions and methods for reducing overdose | INTELLIPHARMACEUTICS CORP. (CA) | 2020-05-19 | — | — | US | disclosed |
| US-20150359747-A1 | ABUSE-PROOFED DOSAGE FORM | Grünenthal GmbH (DE) | 2015-12-17 | — | — | US | disclosed |
| WO-2015191501-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS, INC. (US) | 2015-12-17 | — | — | WO | disclosed |
| US-20150352061-A1 | METHODS AND COMPOSITIONS FOR INTERFERING WITH EXTRACTION OR CONVERSION OF A DRUG SUSCEPTIBLE TO ABUSE | ACURA PHARMACEUTICALS, INC. (US) | 2015-12-10 | — | — | US | disclosed |
| US-20150265536-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY(EPSILON-CAPROLACTONE) AND POLYETHYLENE OXIDE | PURDUE PHARMA L.P. (US) | 2015-09-24 | — | — | US | disclosed |
| US-20150250733-A1 | ORAL DRUG DELIVERY FORMULATIONS | ODIDI ISA (CA) | 2015-09-10 | — | — | US | disclosed |
| US-20140356294-A1 | DOSAGE THAT IS SAFEGUARDED FROM ABUSE | Grünenthal GmbH (DE) | 2014-12-04 | — | — | US | disclosed |
| EP-2787978-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY (EPSILON- CAPROLACTONE) AND POLYETHYLENE OXIDE | Purdue Pharma LP (US) | 2014-10-15 | — | — | EP | disclosed |
| WO-2014140231-A1 | ABUSE RESISTANT CAPSULE | WENGNER SIMONE (DE) | 2014-09-18 | — | — | WO | disclosed |
| WO-2013084059-A1 | PHARMACEUTICAL DOSAGE FORMS COMPRISING POLY (EPSILON- CAPROLACTONE) AND POLYETHYLENE OXIDE | PURDUE PHARMA L.P. (US) | 2013-06-13 | — | — | WO | disclosed |